RENOVARO INC. - COMMON STOCK

Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience

20 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer

07 Apr 2022 05:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit

05 Apr 2022 05:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences and Caring Cross Announce a Partnership to Potentially Increase the Effectiveness of a CAR-T Approach for HIV Cure Currently Being Studied in Humans

15 Mar 2022 06:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors

03 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 month

18 Oct 2021 06:00:01 By Nasdaq GlobeNewswire

Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity

15 Oct 2021 17:00:00 By Nasdaq GlobeNewswire

Fireside Chat with Enochian BioSciences’ CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

12 Oct 2021 17:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection

27 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences to Present to Investors at the H.C. Wainwright 23rd Annual Investment Conference

13 Sep 2021 06:00:01 By Nasdaq GlobeNewswire

Distinguished Scientific and Public Health Leaders to Join Enochian BioSciences’ Scientific Advisory Board for Potential Inhaled Treatment and Prevention of All COVID-19 and Influenza Variants

30 Aug 2021 06:00:00 By Nasdaq GlobeNewswire

Distinguished Scientific and Clinical Leader to Join Enochian BioSciences’ Hepatitis B Cure Scientific Advisory Board

23 Aug 2021 09:18:10 By Nasdaq GlobeNewswire

Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer

20 Jul 2021 06:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

12 Jul 2021 06:00:01 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

30 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology

21 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

14 Jun 2021 13:53:19 By Nasdaq GlobeNewswire

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure

14 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

12 May 2021 15:29:11 By Nasdaq GlobeNewswire

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

12 May 2021 07:00:01 By Nasdaq GlobeNewswire